Ikaria Backers Buy INO, Create Model for Self-Funding Discovery
This article was originally published in Start Up
Executive Summary
Ikaria's private-equity funded acquisition of INO Therapeutics will allow the company to self-fund its continuing discovery programs while acting as a magnet for additional external commercial or clinical stage projects.